Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer

被引：0
|
作者：
Panasci, LC [1 ]
机构：
[1] Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 15期
关键词：
D O I：
10.1200/JCO.2006.05.7562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2392 / 2392
页数：1
相关论文
共 50 条
  • [1] Chemotherapy use for hormone receptor-positive, node-negative breast cancer
    Hassett, M. J.
    Hughes, M. E.
    Niland, J. C.
    Edge, S. B.
    Theriault, R. L.
    Wong, Y.
    Wilson, J.
    Carter, B. W.
    Blayney, D. W.
    Weeks, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
    Fisher, B
    Dignam, J
    Wolmark, N
    DeCillis, A
    Emir, B
    Wickerham, DL
    Bryant, J
    Dimitrov, NV
    Abramson, N
    Atkins, JN
    Shibata, H
    Deschenes, L
    Margolese, RG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (22): : 1673 - 1682
  • [3] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
    Atkins, CD
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (06) : 468 - 468
  • [4] Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
    Hassett, Michael J.
    Hughes, Melissa E.
    Niland, Joyce C.
    Edge, Stephen B.
    Theriault, Richard L.
    Wong, Yu-Ning
    Wilson, John
    Carter, W. Bradford
    Blayney, Douglas W.
    Weeks, Jane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5553 - 5560
  • [5] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer - Response
    Dignam, J
    Fisher, B
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (06): : 468 - 469
  • [6] Conversion to node-negative after neoadjuvant chemotherapy is a surrogate prognostic marker in patients with hormone receptor-positive breast cancer
    Takahashi, Y.
    Hayashi, N.
    Matsuda, N.
    Kajiura, Y.
    Yoshida, A.
    Yagata, H.
    Nakamura, S.
    Suzuki, K.
    Tsunoda, H.
    Yamauchi, H.
    CANCER RESEARCH, 2013, 73
  • [7] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Paik, Soonmyung
    Tang, Gong
    Shak, Steven
    Kim, Chungyeul
    Baker, Joffre
    Kim, Wanseop
    Cronin, Maureen
    Baehner, Frederick L.
    Watson, Drew
    Bryant, John
    Costantino, Joseph P.
    Geyer, Charles E., Jr.
    Wickerham, D. Lawrence
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) : 3726 - 3734
  • [8] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    Ando, Kenju
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Kawamura, Yukino
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
  • [9] Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients
    Chu, Quyen D.
    Holm, Neal T.
    Madumere, Prince
    Johnson, Lester W.
    Abreo, Fleurette
    Li, Benjamin D. L.
    SURGERY, 2011, 149 (02) : 193 - 199
  • [10] Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
    Jacqueline Tsai
    Danielle Bertoni
    Tina Hernandez-Boussard
    Melinda L. Telli
    Irene L. Wapnir
    Annals of Surgical Oncology, 2016, 23 : 3310 - 3316
12345